top of page

Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan LungCancer PCR Panel...

TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent for multiple antineoplastic agents, was filed in Japan as a companion diagnostic for RetevmoTM (selpercatinib).

Read the full press release below:

Download PDF • 434KB


bottom of page